Across TCGA pan-cancer cohorts, COL18A1-AS1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated COL18A1-AS1 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher COL18A1-AS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COL18A1-AS1 expression acts as an unfavorable survival marker.
COAD are the cancer types where COL18A1-AS1 Mutation most reproducibly stratifies survival.